In a drive to find innovative solutions and instill a collaborative approach to understanding SCD, FSCDR holds its Annual Sickle Cell Disease Research and Educational Symposium. For 12 years now, with participation from the world’s leading physicians, scientists, public health professionals, researchers, patients, and caregivers, the Symposium has proven itself an essential platform for the evolution of SCD treatment. A multifaceted approach to finding a dependable cure is paramount, as it stimulates new therapies while informing international members of the latest findings.
Engagement from the world’s leading pharmaceutical and medical research companies, including Global Blood Therapeutics, Novartis, Pfizer, Medunik, and Bioverativ, shows a desire for interactive education, sharing of best practices, and exploring novel approaches to dealing with this age-old disease that goes beyond theory to develop practical, real-life solutions.
Lanetta Bronté-Hall, MD, MPH, MSPH is responsible for strategic planning, scientific, and administrative oversight of the Foundation for Sickle Cell Disease Research (FSCDR). She is a leading national and international researcher and population health scientist in the field of sickle cell disease, rare blood disorders, community-based participatory research, and chronic disease management. Dr. Bronté-Hall has extensive experience in developing programs that are closely aligned with the recruitment and retention of underserved and underrepresented populations for treatment of Sickle Cell Disease and Breast Cancer, research and clinical trials. She is currently President and CEO of the Foundation for Sickle Cell Disease Research (FSCDR), Chief Health Officer (CHO) of the Sickle Care and Research Network, FSCDR, LLC, an independent full- service outpatient medical treatment and clinical trials center that offers medical care and coordinated care for underserved populations. Dr. Bronté-Hall has a faculty appointment at the University of Miami, Miller School of Medicine as an Associate Professor in the Department of Public Health Sciences, Department of Health Services Research and Policy.
LANETTA BRONTÉ-HALL, MD, MPH, MSPH - FSCDR PRESIDENT
Thoracic surgeon and medical professor Dr. Julius W. Garvey was born on September 17, 1933 in Kingston, Jamaica to United Negro Improvement Association founder Marcus Garvey, and activist Amy Jacques Garvey. The younger of two sons, Garvey was raised in Jamaica. He attended Wolmer’s Trust High School for Boys in Kingston, graduating in 1950. He then earned his B.S. degree from McGill University in Montréal, Quebec in 1957, and his M.D., C.M. degree from McGill University Faculty of Medicine in 1961.
Garvey began his medical career by interning at The Royal Victoria Hospital in Montréal in 1961. In 1962, he began his first residency in surgery at The Mount Sinai Hospital of New York, completing the residency in 1965. Garvey completed a subsequent residency in surgery at the Harlem Hospital Center in 1968, and in thoracic & cardiovascular surgery at the University of Maryland Hospital in Baltimore, Maryland in 1970. Upon completing his residencies, Garvey became an instructor in surgery at the Columbia University College of Physicians and Surgeons in 1971. The following year, he joined the Albert Einstein College of Medicine as an instructor in surgery, quickly gaining an assistant professor of surgery position. While teaching at Columbia University and the Albert Einstein College of Medicine, Garvey also served as an attending surgeon in cardiothoracic surgery at the Harlem Hospital Center and Montefiore Hospital, as well as associate attending and head of thoracic surgery at the Montefiore Morrisania Affiliate. In 1974, Garvey was named attending-in-charge of thoracic surgery at Queens Hospital Center, and also became an attending surgeon in thoracic and cardiovascular surgery at the Long Island Jewish Medical Center. Garvey became the Long Island Jewish Medical Center’s acting program director for the Division of Cardiothoracic Surgery from 1980 to 1982, and assistant professor of surgery at State University of New York at Stony Brook from 1978 to 1988. He began his private practice in 1983. Garvey was chief of thoracic and vascular surgery at Queens Hospital Center from 1993 to 2006, and chief of vascular and thoracic surgery at Wyckoff Heights Medical Center from 2000 to 2004. In addition to his other medical appointments, Garvey has served as an attending surgeon at North Shore University Hospital, Franklin General Hospital, Massapequa General Hospital, Catholic Medical Centers, and Little Neck Community Hospital.
Garvey was a certified fellow of the Royal College of Surgeons, the American College of Surgeons, the International College of Surgeons, and the American College of Chest Physicians, as well as a diplomate of the Board of Cardiothoracic & Vascular Surgery, the American Board of Surgery, the American Academy of Wound Management, and the American College of Phlebology.
JULIUS GARVEY, MD - 2019 KEYNOTE SPEAKER
Dr. Minniti is Professor of Clinical Medicine and Pediatrics at Einstein College of Medicine. She is the Director of the Sickle Cell Center for Adults at Montefiore Hospital, whose mission is to provide exceptional, seamless, comprehensive, compassionate and individualized care, education, counseling and research for people living with sickle cell disease. Dr. Minniti is a clinical trial specialist and a translational researcher who believes that the best way to provide care for SCD patients is on a continuum, from birth to adulthood.
The focus of her research is in understanding mechanisms that lead to end organ damage in order to identify early biomarkers and targeted therapies. Her interests have spanned from stroke to pulmonary hypertension and most recently, she has focused on leg ulcers as they represent a window into the vasculopathy in SCD. She aims to develop pathogenetically based therapeutic approaches for preventing and treating SCD-related end organ damage.
CATERINA P. MINNITI, MD - 2019 SCIENTIFIC CHAIR
Courtney Fitzhugh received her B.S. magna cum laude from the University of California, Los Angeles in 1996, and her M.D. from the University of California, San Francisco in 2001. During medical school, Dr. Fitzhugh participated in the NIH Clinical Research Training Program, where she studied with Dr. John Tisdale at the NHLBI. After receiving her M.D., Dr. Fitzhugh completed a joint residency in internal medicine and pediatrics at Duke University Medical Center, and in 2005 she did a combined adult hematology and pediatric hematology-oncology fellowship at the NIH and Johns Hopkins Hospital. Dr. Fitzhugh returned to the NHLBI in 2007 and was appointed as Assistant Clinical Investigator in 2012 and Clinical Tenure Track Investigator in 2016. She is a member of the American Society of Hematology.
COURTNEY FITZHUGH, M.D - 2019 SCIENTIFIC KEYNOTE
Director, Pediatric Stem Cell Transplantation / Associate Professor of Pediatrics, Columbia University College of Physicians and Surgeons
MONICA BHATIA, MD - EDUCATIONAL SESSION CHAIR
Associate Professor of Medicine / Director of the Center for Excellence in Sickle Cell Disease
ELIZABETH S. KLINGS, MD - EDUCATIONAL SESSION CHAIR
Wally R. Smith, MD is the first recipient of The Florence Neal Cooper Smith Professor of Sickle Cell Disease, the second African-American female chair in the United States. He also serves as the Vice-Chairman for Research of the Division of General Internal Medicine and is the former Scientific Director of the Center on Health Disparities at Virginia Commonwealth University. In addition he was a member of the Institute of Medicine’s Committee on Standards for Trustworthy Guidelines. He has authored over 100 publications, and served as an investigator on over 50 externally funded grants and contracts, including principal investigator on 26 federal or foundation-funded grants and contracts
WALLY R. SMITH, MD - EDUCATIONAL SESSION CHAIR
Patrick Hines, MD PhD is an Assistant Professor of Pediatric Critical Care Medicine and Associate in the Department of Physiology, Wayne State University School of Medicine., Children’s Hospital of Michigan. Previous business and technology consultant for Quantum Genomics, University of North Carolina at Chapel Hill – based startup specializing in models of human diseases. Past chairman of the board of directors for the SNMA.
PATRICK HINES, MD PHD - EDUCATIONAL SESSION CHAIR
Foundation for Sickle Cell Disease Research
EBONI DAVIS, ARNP - EDUCATIONAL SESSION CHAIR
Dr. Sheehan is an Assistant Professor of Pediatrics at Baylor College of Medicine, division of Hematology/oncology. After completing a PhD in Biochemistry, Dr. Sheehan went on to medical school at Emory University School of Medicine; there, she decided to pursue a career in SCD patient care and research. Dr. Sheehan’s laboratory uses genomics to unravel the mechanisms of hemoglobin switching, in order to develop new fetal hemoglobin inducing agents to treat people with sickle cell disease. Her work has led to a clinical trial of metformin as a fetal hemoglobin inducing agent in patients with hemoglobinopathies.
VIVIEN SHEEHAN, MD, PHD - EDUCATIONAL SESSION CHAIR
Academy of Neurosurgical Physicians
ANTHONY HALL, MDCM, FACS, FAANS EDUCATIONAL SESSION CHAIR
Payal C. Desai, MD¬¬ is an Associate Professor of Internal Medicine, Division of Hematology, at the Ohio State University, Arthur G. James Cancer Hospital, Wexner Medical Center, where she is Director of Sickle Cell Research.
Dr. Desai received her medical degree from the University of Louisville School of Medicine, Louisville, KY. She completed her residency at University of Louisville in Louisville, KY and her fellowship in hematology and oncology at University of North Carolina at Chapel Hill, Chapel Hill, NC. During her fellowship, she pursued disease specific training in sickle cell disease on a T32 training award. She is board certified in Internal Medicine and Hematology.
Dr. Desai has authored or co-authored 26 papers and 32 abstracts, primarily in the field of sickle cell research. Dr. Desai is a 2008 Annual Resident Teacher Award Winner, the 2011 American Society of Hematology Abstract Achievement Award Winner, the 2015 Dr. Richard and Lynda Goldberg Award for Clinical Excellence Winner, the 2016 Fellowship Benign Hematology Lecture Award and the 2016, 2017 and 2018 Awardee for the Faith Thomas Foundation Partnership Award for Sickle Cell Awareness. Under her leadership, the Ohio State Comprehensive Adult Sickle Cell Program is the only joint commission certified program in the country.
Dr. Desai holds professional memberships with the American Society of Hematology and the Sickle Cell Adult Provider Network (SCAPN). She is currently vice president of the Sickle Cell Adult Provider Network. and founder of the Sickle Cell Provider Network, Jr, an organization committed to the development of young researchers in the field of sickle cell disease. She has participated in numerous multicentered studies and currently the principal investigator on over 10 studies focused on sickle cell disease.